Assignee
OLIX PHARMACEUTICALS INC
KR·14 granted patents·8 pending applications·34 citations·filing 2013–2022
Top patents by PatentIndex Score
22 records- 0187US10358648B2Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1OLIX PHARMACEUTICALS INC·Filed 2017·Granted Jul 23, 2019·8 cites·14 claims
- 0287US10064801B2RNA complexes that inhibit melanin productionOLIX PHARMACEUTICALS INC·Filed 2016·Granted Sep 4, 2018·8 cites·25 claims
- 0386US10125362B2RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use thereforOLIX PHARMACEUTICALS INC·Filed 2013·Granted Nov 13, 2018·9 cites·15 claims
- 0486US10059949B2Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3OLIX PHARMACEUTICALS INC·Filed 2016·Granted Aug 28, 2018·8 cites·20 claims
- 0569US10301628B2Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factorOLIX PHARMACEUTICALS INC·Filed 2017·Granted May 28, 2019·1 cites·12 claims
- 0668US10883105B2RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use thereforOLIX PHARMACEUTICALS INC·Filed 2018·Granted Jan 5, 2021·0 cites·15 claims
- 0767US10947541B2Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1OLIX PHARMACEUTICALS INC·Filed 2019·Granted Mar 16, 2021·0 cites·19 claims
- 0865US2021207137A1Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use thereforOLIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0962US10829761B2Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factorOLIX PHARMACEUTICALS INC·Filed 2019·Granted Nov 10, 2020·0 cites·21 claims
- 1060US2024124879A1Rnai agent for inhibiting hbv expression and use thereofOLIX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1160US2020123548A1Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfbOLIX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1258US2019119672A1Small interference rna complex with increased intracellular transmission capacityOLIX PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1356US11591600B2Long double-stranded RNA for RNA interferenceOLIX PHARMACEUTICALS INC·Filed 2018·Granted Feb 28, 2023·0 cites·19 claims
- 1456US2022380774A1Asymmetric sirna inhibiting expression of pd-1OLIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1555US10512600B2RNA complexes that inhibit melanin productionOLIX PHARMACEUTICALS INC·Filed 2018·Granted Dec 24, 2019·0 cites·19 claims
- 1653US10590423B2Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3OLIX PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·0 cites·19 claims
- 1753US2025179498A1Rnai agent targeting marc1 gene, and use thereofOLIX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1852US11118184B2Asymmetric siRNA for inhibiting expression of male pattern hair loss target geneOLIX PHARMACEUTICALS INC·Filed 2018·Granted Sep 14, 2021·0 cites·6 claims
- 1949US11040057B2Pharmaceutical compositions and methods for potentiating gene silencingOLIX PHARMACEUTICALS INC·Filed 2017·Granted Jun 22, 2021·0 cites·18 claims
- 2048US10519449B2Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFBOLIX PHARMACEUTICALS INC·Filed 2017·Granted Dec 31, 2019·0 cites·12 claims
- 2147US2024093188A1RNAi AGENT TARGETING MYD88 AND USE THEREOFOLIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2240US2024024492A1Nucleic acid molecule for induction of asymmetric rnai for inhibiting expression of ror-betaOLIX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when OLIX PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →